The Impact of Obesity Medicines on Drug Development

If positive, it would be the first trial showing that an obesity drug does lead to positive cardiovascular outcomes for people with obesity. I talked with one of the executives at Novo about select and he said it could have the potential to be quote, a game changer or a landmark trial. So obviously that's coming from them. But there is a general consensus across the whole industry of obesity drug makers that this could be a really important trial.